Thus far, the CANTOS trial has proved promising since inhibition of IL-1β reduces the total number of serious cardiovascular events in patients with prior MI history (416); however, it has not examined whether IL-1β inhibition by canakinumab improves characteristics of NASH. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.